Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbHThese are investigational agents and are not approved by the EMA, FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that these investigational agents will become commercially available.
| Compound | Tumor Type | Relevant Pathway | Highest Phase of Development | Location |
|---|---|---|---|---|
| DS-8201 | Breast Cancer, Gastric Cancer | HER2 | Phase 1 | US / Japan |
| U3-1402 | Breast Cancer | HER2 | Phase 1 | Japan |
| DS-7300 | Solid Tumours | B7-H3 | Preclinical | -- |
| DS-1062 | Solid Tumours | TROP2 | Preclinical | -- |
| Project 5 | Solid Tumours | Undisclosed | Preclinical | -- |
| Project 6 | Solid Tumours | Undisclosed | Preclinical | -- |
| Compound | Tumor Type | Relevant Pathway | Highest Phase of Development | Location |
|---|---|---|---|---|
| Quizartinib (AC220) | Newly-Diagnosed Acute Myeloid Leukemia | FLT3 | Phase 3 | US / EU/ Asia |
| Quizartinib (AC220) | Relapsed/Refractory AML | FLT3 | Phase 3 | US / EU/ Asia |
| Quizartinib (AC220) | Relapsed/Refractory AML | FLT3 | Phase 1 | Japan |
| DS-3032 | AML, Acute Lymphotic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome (MDS) | MDM2 | Phase 1 | US |
| DS-3032 | Solid Tumours, Lymphoma | MDM2 | Phase 1 | Japan |
| DS-3201 | AML, ALL | EZH1/2 | Phase 1 | US |
| DS-3201 | Non-Hodgkin's Lymphoma | EZH1/2 | Phase 1 | Japan |
| PLX51107 | AML, MDS, Lymphoma, Solid Tumours | BRD4 | Phase 1 | US |
| DS-1001 | AML | IDH1 | Preclinical | -- |
| Compound | Tumor Type | Relevant Pathway | Highest Phase of Development | Location |
|---|---|---|---|---|
| Pexidartinib (PLX3397) | Tenosynovial Giant Cell Tumor (TGCT)*, FDA Breakthrough Designation | CSF-1R | Phase 3 | US/EU |
| Pexidartinib (PLX3397) | Glioblastoma | CSF-1R, c-KIT | Phase 2 | US |
| Pexidartinib (PLX3397) | Melanoma | c-KIT | Phase 1/2 | Asia |
| Pexidartinib (PLX3397) | Solid Tumors | CSF-1R | Phase 1 | Asia |
| Pexidartinib (PLX3397) | Solid Tumors, Melanoma | CSF-1R | Phase 1/2 | US |
| Pexidartinib (PLX3397) [in combination with pembrolizumab] | Solid Tumors, Melanoma | CSF-1R | Phase 1/2 | US |
| Patritumab (U3-1287) | Head and Neck Cancer | HER3 | Phase 2 | EU |
| DS-1647 | Glioblastoma SAKIGAKE Designation | Oncolytic HSV-1 | Phase 2 | Japan |
| PLX7486 | Solid Tumors | FMS/TRK | Phase 1 | US |
| PLX8394 | Solid Tumor | BRAF | Phase 1 | US |
| DS-8273 | Solid Tumors | DR5 | Phase 1 | US |
| DS-6051 | Solid Tumors | NTRK/ROS1 | Phase 1 | US/Japan |
| PLX9486 | Solid Tumors | KIT | Phase 1 | US |
| PLX73086 | TGCT | CSF-1R | Phase 1 | US |
| DS-1123 | Solid Tumors | FGFR2 | Phase 1 | Japan |
| DS-1001 | Gliomas | IDH1 | Phase 1 | Japan |
*Tenosynovial giant cell tumor (TGCT) is also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).